Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


20.02.2017

1 Acta Cytol
1 AJR Am J Roentgenol
1 Am J Clin Pathol
1 Am J Epidemiol
1 Am J Surg
1 Am J Surg Pathol
1 Ann Oncol
1 Ann Surg
4 Ann Surg Oncol
2 Anticancer Res
7 BMC Cancer
2 BMJ
4 Br J Cancer
3 Breast Cancer
1 Breast Cancer (Dove Med Press)
4 Breast Cancer Res
21 Breast Cancer Res Treat
2 Breast J
7 Cancer
6 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
2 Cancer Res
12 Clin Breast Cancer
2 Clin Cancer Res
2 Curr Treat Options Oncol
1 Eur J Cancer
1 Eur J Surg Oncol
1 Int J Cancer
2 Int J Oncol
1 J Biol Chem
3 J Clin Oncol
3 J Natl Cancer Inst
1 J Pathol
4 J Surg Oncol
5 JAMA
1 Lancet
1 Lancet Oncol
1 NPJ Breast Cancer
3 Oncogene
3 Oncol Rep
2 Oncology
3 Oncology (Williston Park)
13 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Cytol

  1. HANDA U, Kundu R, Dimri K
    Cutaneous Metastasis: A Study of 138 Cases Diagnosed by Fine-Needle Aspiration Cytology.
    Acta Cytol. 2017;61:47-54.
    PubMed     Text format     Abstract available


    AJR Am J Roentgenol

  2. AMINOLOLAMA-SHAKERI S, Flowers CI, McLaren CE, Wisner DJ, et al
    Can Radiologists Predict the Presence of Ductal Carcinoma In Situ and Invasive Breast Cancer?
    AJR Am J Roentgenol. 2017 Feb 15:1-7. doi: 10.2214/AJR.16.16073.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  3. SERDY KM, Leone JP, Dabbs DJ, Bhargava R, et al
    Male Breast Cancer.
    Am J Clin Pathol. 2017;147:110-119.
    PubMed     Text format    


    Am J Epidemiol

  4. RAEBEL MA, Zeng C, Cheetham TC, Smith DH, et al
    Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women.
    Am J Epidemiol. 2017;185:264-273.
    PubMed     Text format    


    Am J Surg

  5. BICHOO RA, Jha CK, Mishra A
    Letter to editor in response to the article entitled "Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and No
    Am J Surg. 2017 Jan 11. pii: S0002-9610(16)30693.
    PubMed     Text format    


    Am J Surg Pathol

  6. DILL EA, Gru AA, Atkins KA, Friedman LA, et al
    PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Am J Surg Pathol. 2017;41:334-342.
    PubMed     Text format     Abstract available


    Ann Oncol

  7. CURIGLIANO G, Goldhirsch A
    Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    Ann Surg

  8. WONG SM, Freedman RA, Sagara Y, Aydogan F, et al
    Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
    Ann Surg. 2017;265:581-589.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  9. CHEN HA, Chang YW, Tseng CF, Chiu CF, et al
    Erratum to: E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer.
    Ann Surg Oncol. 2017 Feb 3. doi: 10.1245/s10434-017-5769.
    PubMed     Text format    

  10. TEN WOLDE B, Kuiper M, de Wilt JH, Strobbe LJ, et al
    Postoperative Complications After Breast Cancer Surgery are Not Related to Age.
    Ann Surg Oncol. 2017 Feb 6. doi: 10.1245/s10434-016-5726.
    PubMed     Text format     Abstract available

  11. SCHAVERIEN MV, Butler CE
    Complications in DIEP Flap Breast Reconstruction After Mastectomy for Breast Cancer: A Prospective Cohort Study Comparing Unilateral and Bilateral Reconstructions.
    Ann Surg Oncol. 2017 Feb 13. doi: 10.1245/s10434-017-5809.
    PubMed     Text format    

  12. LIANG Y, Chen X, Zhan W, Garfield DH, et al
    Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?
    Ann Surg Oncol. 2017 Feb 6. doi: 10.1245/s10434-017-5798.
    PubMed     Text format     Abstract available


    Anticancer Res

  13. GIPPONI M, Baldelli I, Atzori G, Fregatti P, et al
    Tumescent Anesthesia in Skin- and Nipple-sparing Mastectomy: Results of a Prospective Clinical Study.
    Anticancer Res. 2017;37:349-352.
    PubMed     Text format     Abstract available

  14. SCHRODER L, Koch J, Mahner S, Kost BP, et al
    The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7).
    Anticancer Res. 2017;37:95-102.
    PubMed     Text format     Abstract available


    BMC Cancer

  15. LAVENDER N, Yang J, Chen SC, Sai J, et al
    The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo.
    BMC Cancer. 2017;17:88.
    PubMed     Text format     Abstract available

  16. VIERKANT RA, Degnim AC, Radisky DC, Visscher DW, et al
    Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.
    BMC Cancer. 2017;17:84.
    PubMed     Text format     Abstract available

  17. BARBA M, Vici P, Pizzuti L, Di Lauro L, et al
    Body mass index modifies the relationship between gamma-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
    BMC Cancer. 2017;17:101.
    PubMed     Text format     Abstract available

  18. WENGSTROM Y, Bolam KA, Mijwel S, Sundberg CJ, et al
    Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy.
    BMC Cancer. 2017;17:100.
    PubMed     Text format     Abstract available

  19. EFFI AB, Aman NA, Koui BS, Koffi KD, et al
    Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    BMC Cancer. 2017;17:115.
    PubMed     Text format     Abstract available

  20. SINN HP, Schneeweiss A, Keller M, Schlombs K, et al
    Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    BMC Cancer. 2017;17:124.
    PubMed     Text format     Abstract available

  21. JAISWAL R, Johnson MS, Pokharel D, Krishnan SR, et al
    Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion.
    BMC Cancer. 2017;17:104.
    PubMed     Text format     Abstract available


    BMJ

  22. WISE J
    GPs are unsure about prescribing tamoxifen to prevent breast cancer.
    BMJ. 2017;356:j772.
    PubMed     Text format    

  23. WISE J
    NICE recommends controlled intrabeam use for breast cancer after three year delay.
    BMJ. 2017;356:j725.
    PubMed     Text format    


    Br J Cancer

  24. YIP C, Foidart P, Somja J, Truong A, et al
    MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  25. CATALANO OA, Horn GL, Signore A, Iannace C, et al
    PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  26. PARK YM, O'Brien KM, Zhao S, Weinberg CR, et al
    Gestational diabetes mellitus may be associated with increased risk of breast cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  27. DE PLACIDO S, De Angelis C, Giuliano M, Pizzi C, et al
    Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
    Br J Cancer. 2017 Feb 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer

  28. SUGIE T, Toi M
    Antitumor immunity and advances in cancer immunotherapy.
    Breast Cancer. 2017;24:1-2.
    PubMed     Text format    

  29. KOIKE Y, Ohta Y, Saitoh W, Yamashita T, et al
    Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Breast Cancer. 2017 Jan 31. doi: 10.1007/s12282-017-0757.
    PubMed     Text format     Abstract available

  30. LUO M, Ding L, Li Q, Yao H, et al
    miR-668 enhances the radioresistance of human breast cancer cell by targeting IkappaBalpha.
    Breast Cancer. 2017 Jan 30. doi: 10.1007/s12282-017-0756.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  31. MURILLO-ORTIZ B, Martinez-Garza S, Suarez Garcia D, Castillo Valenzuela RD, et al
    Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women.
    Breast Cancer (Dove Med Press). 2017;9:21-27.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  32. MUSOLINO A, Campone M, Neven P, Denduluri N, et al
    Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
    Breast Cancer Res. 2017;19:18.
    PubMed     Text format     Abstract available

  33. BIANCHINI G, Kiermaier A, Bianchi GV, Im YH, et al
    Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Breast Cancer Res. 2017;19:16.
    PubMed     Text format     Abstract available

  34. BLACK KZ, Nichols HB, Eng E, Rowley DL, et al
    Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study.
    Breast Cancer Res. 2017;19:11.
    PubMed     Text format     Abstract available

  35. HU Z, Mao JH, Curtis C, Huang G, et al
    Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
    Breast Cancer Res. 2017;19:17.
    PubMed     Text format    


    Breast Cancer Res Treat

  36. PARK B, Sohn JY, Yoon KA, Lee KS, et al
    Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4142.
    PubMed     Text format     Abstract available

  37. YEO SK, French R, Spada F, Clarkson R, et al
    Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4149.
    PubMed     Text format     Abstract available

  38. LIM EA, Gunther JE, Kim HK, Flexman M, et al
    Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4150.
    PubMed     Text format     Abstract available

  39. MARINAC CR, Nelson SH, Flatt SW, Natarajan L, et al
    Sleep duration and breast cancer prognosis: perspectives from the Women's Healthy Eating and Living Study.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4140.
    PubMed     Text format     Abstract available

  40. THOMAS JS, Hanby AM, Russell N, van Tienhoven G, et al
    The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4145.
    PubMed     Text format     Abstract available

  41. HWANG KT, Kim YA, Kim J, Chu AJ, et al
    The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4153.
    PubMed     Text format     Abstract available

  42. LERNER-ELLIS J, Donenberg T, Ahmed H, George S, et al
    A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4148.
    PubMed     Text format     Abstract available

  43. INWALD EC, Ortmann O, Koller M, Zeman F, et al
    Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4151.
    PubMed     Text format     Abstract available

  44. CARMICHAEL H, Matsen C, Freer P, Kohlmann W, et al
    Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4122.
    PubMed     Text format     Abstract available

  45. HSIEH YC, Tu SH, Su CT, Cho EC, et al
    A polygenic risk score for breast cancer risk in a Taiwanese population.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4144.
    PubMed     Text format     Abstract available

  46. GOORTS B, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4155.
    PubMed     Text format     Abstract available

  47. SONG SE, Shin SU, Moon HG, Ryu HS, et al
    MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4143.
    PubMed     Text format     Abstract available

  48. DETHLEFSEN C, Pedersen KS, Hojman P
    Every exercise bout matters: linking systemic exercise responses to breast cancer control.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4129.
    PubMed     Text format     Abstract available

  49. SHAITELMAN SF, Chiang YJ, Griffin KD, De Snyder SM, et al
    Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4116.
    PubMed     Text format    

  50. PARIKH RP, Odom EB, Yu L, Colditz GA, et al
    Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4146.
    PubMed     Text format     Abstract available

  51. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Weltzien EK, et al
    Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4133.
    PubMed     Text format     Abstract available

  52. WITZEL I, Marx AK, Muller V, Wikman H, et al
    Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.
    Breast Cancer Res Treat. 2017 Feb 6. doi: 10.1007/s10549-017-4135.
    PubMed     Text format     Abstract available

  53. VALLE LF, Agarwal S, Bickel KE, Herchek HA, et al
    Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2017 Feb 3. doi: 10.1007/s10549-017-4118.
    PubMed     Text format     Abstract available

  54. PEREZ M, Schootman M, Hall LE, Jeffe DB, et al
    Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life.
    Breast Cancer Res Treat. 2017 Jan 28. doi: 10.1007/s10549-017-4121.
    PubMed     Text format     Abstract available

  55. VAN UDEN DJ, Bretveld R, Siesling S, de Wilt JH, et al
    Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4119.
    PubMed     Text format     Abstract available

  56. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.
    Breast Cancer Res Treat. 2017 Feb 2. doi: 10.1007/s10549-017-4106.
    PubMed     Text format     Abstract available


    Breast J

  57. CORDEIRO CN, Gemignani ML
    Breast Cancer in Pregnancy: Avoiding Fetal Harm When Maternal Treatment Is Necessary.
    Breast J. 2017 Feb 13. doi: 10.1111/tbj.12780.
    PubMed     Text format     Abstract available

  58. SEOL YM, Kim DY, Kim HJ, Choi YJ, et al
    Reversible Posterior Leukoencephalopathy Syndrome after Eribulin Mesylate Chemotherapy for Breast Cancer.
    Breast J. 2017 Jan 31. doi: 10.1111/tbj.12776.
    PubMed     Text format    


    Cancer

  59. BARCENAS CH, Raghavendra A, Sinha AK, Syed MP, et al
    Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Cancer. 2017 Feb 15. doi: 10.1002/cncr.30618.
    PubMed     Text format     Abstract available

  60. YEE MK, Sereika SM, Bender CM, Brufsky AM, et al
    Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer.
    Cancer. 2017 Feb 15. doi: 10.1002/cncr.30575.
    PubMed     Text format     Abstract available

  61. PEPPERCORN J, Horick N, Houck K, Rabin J, et al
    Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30629.
    PubMed     Text format     Abstract available

  62. SADIM M, Xu Y, Selig K, Paulus J, et al
    Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30628.
    PubMed     Text format     Abstract available

  63. DONALDSON AR, Shetty S, Wang Z, Rivera CL, et al
    Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30592.
    PubMed     Text format     Abstract available

  64. MILLER JA, Kotecha R, Ahluwalia MS, Mohammadi AM, et al
    Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30616.
    PubMed     Text format     Abstract available

  65. RAGHAVENDRA A, Sinha AK, Le-Petross HT, Garg N, et al
    Mammographic breast density is associated with the development of contralateral breast cancer.
    Cancer. 2017 Jan 30. doi: 10.1002/cncr.30573.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  66. CONROY SM, Shariff-Marco S, Koo J, Yang J, et al
    Racial/Ethnic Differences in the Impact of Neighborhood Social and Built Environment on Breast Cancer Risk: The Neighborhoods and Breast Cancer Study.
    Cancer Epidemiol Biomarkers Prev. 2017 Feb 14. pii: cebp.0935.2016.
    PubMed     Text format     Abstract available

  67. DABBOUS FM, Dolecek TA, Berbaum ML, Friedewald SM, et al
    Impact of a False-Positive Screening Mammogram on Subsequent Screening Behavior and Stage at Breast Cancer Diagnosis.
    Cancer Epidemiol Biomarkers Prev. 2017 Feb 9. doi: 10.1158/1055-9965.EPI-16-0524
    PubMed     Text format     Abstract available

  68. EVANS DG, Harkness E, Lalloo F
    The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Risk-Letter.
    Cancer Epidemiol Biomarkers Prev. 2017;26:284.
    PubMed     Text format    

  69. SHARIFF-MARCO S, Von Behren J, Reynolds P, Keegan TH, et al
    Impact of social and built environment factors on body size among breast cancer survivors: the Pathways Study.
    Cancer Epidemiol Biomarkers Prev. 2017 Feb 2. pii: cebp.0932.2016.
    PubMed     Text format     Abstract available

  70. CONROY SM, Clarke C, Yang J, Shariff-Marco S, et al
    Contextual impact of neighborhood obesogenic factors on postmenopausal breast cancer: The Multiethnic Cohort.
    Cancer Epidemiol Biomarkers Prev. 2017 Jan 31. pii: cebp.0941.2016.
    PubMed     Text format     Abstract available

  71. VOS JR, Oosterwijk JC, Rookus MA, van der Hout AH, et al
    The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Risk-Response.
    Cancer Epidemiol Biomarkers Prev. 2017;26:285.
    PubMed     Text format    


    Cancer Lett

  72. MONTAGNA E, Palazzo A, Maisonneuve P, Cancello G, et al
    Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Cancer Lett. 2017 Jan 26. pii: S0304-3835(17)30068.
    PubMed     Text format     Abstract available


    Cancer Res

  73. JACKSON W, Sosnoski DM, Ohanessian SE, Chandler P, et al
    The Role of Megakaryocytes in Breast Cancer Metastasis to Bone.
    Cancer Res. 2017 Feb 15. pii: canres.1084.2016.
    PubMed     Text format     Abstract available

  74. ZHOU R, Pantel AR, Li S, Lieberman BP, et al
    [18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple Negative Breast Cancer in Response to Glutaminase Inhibition.
    Cancer Res. 2017 Feb 15. pii: canres.1945.2016.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  75. DENU RA, Burkard ME
    Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome.
    Clin Breast Cancer. 2017 Jan 5. pii: S1526-8209(16)30577.
    PubMed     Text format    

  76. CONVERSANO A, Mazouni C, Thomin A, Gaudin A, et al
    Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma.
    Clin Breast Cancer. 2017 Jan 10. pii: S1526-8209(16)30449.
    PubMed     Text format     Abstract available

  77. ALTUNDAG K
    New Data About First-line All-oral Vinorelbine and Capecitabine in HER2-negative Metastatic Breast Cancer Confirms Results of Meta-analysis.
    Clin Breast Cancer. 2017 Jan 9. pii: S1526-8209(16)30426.
    PubMed     Text format    

  78. MURPHY BL, Boughey JC, Hieken TJ
    Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer.
    Clin Breast Cancer. 2017 Jan 9. pii: S1526-8209(16)30355.
    PubMed     Text format     Abstract available

  79. HWANG KT, Kim J, Kim EK, Jung SH, et al
    Poor Prognosis of Lower Inner Quadrant in Lymph Node-negative Breast Cancer Patients Who Received No Chemotherapy: A Study Based on Nationwide Korean Breast Cancer Registry Database.
    Clin Breast Cancer. 2017 Jan 10. pii: S1526-8209(16)30269.
    PubMed     Text format     Abstract available

  80. NYE L, Rademaker A, Gradishar WJ
    Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Clin Breast Cancer. 2017 Jan 9. pii: S1526-8209(16)30313.
    PubMed     Text format     Abstract available

  81. LI G, Xu Z, Zhuang A, Chang S, et al
    Magnetic Resonance Spectroscopy-Detected Change in Marrow Adiposity Is Strongly Correlated to Postmenopausal Breast Cancer Risk.
    Clin Breast Cancer. 2017 Jan 18. pii: S1526-8209(17)30011.
    PubMed     Text format     Abstract available

  82. SHEPPARD VB, Cavalli LR, Dash C, Kanaan YM, et al
    Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer.
    Clin Breast Cancer. 2017 Jan 6. pii: S1526-8209(16)30571.
    PubMed     Text format     Abstract available

  83. SCHRAMM A, Schochter F, Friedl TW, de Gregorio N, et al
    Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
    Clin Breast Cancer. 2017 Jan 10. pii: S1526-8209(16)30257.
    PubMed     Text format     Abstract available

  84. VAN BASTELAAR J, Theunissen LL, Snoeijs MG, Beets GL, et al
    Flap Fixation Using Tissue Glue or Sutures Appears to Reduce Seroma Aspiration After Mastectomy for Breast Cancer.
    Clin Breast Cancer. 2017 Jan 24. pii: S1526-8209(16)30565.
    PubMed     Text format     Abstract available

  85. GOLSE N, Adam R
    Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results.
    Clin Breast Cancer. 2017 Jan 9. pii: S1526-8209(16)30298.
    PubMed     Text format     Abstract available

  86. ALTUNDAG K
    Genomic Profiling of Brain Metastasis and Matched Primary Triple-negative Breast Cancer.
    Clin Breast Cancer. 2017 Jan 9. pii: S1526-8209(16)30409.
    PubMed     Text format    


    Clin Cancer Res

  87. SHACHAR SS, Deal AM, Weinberg M, Williams GR, et al
    Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane Based Chemotherapy for Early Stage Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2266.2016.
    PubMed     Text format     Abstract available

  88. SINGER CF, Tan YY, Fitzal F, Steger GG, et al
    Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2373.2016.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  89. SHAH AN, Cristofanilli M
    The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Curr Treat Options Oncol. 2017;18:6.
    PubMed     Text format     Abstract available

  90. LAMBERTINI M, Del Mastro L, Viglietti G, Ponde NF, et al
    Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
    Curr Treat Options Oncol. 2017;18:4.
    PubMed     Text format     Abstract available


    Eur J Cancer

  91. FREOUR T, Barriere P, Masson D
    Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Eur J Cancer. 2017;74:1-8.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  92. SAVOLT A, Peley G, Polgar C, Udvarhelyi N, et al
    Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Eur J Surg Oncol. 2017 Jan 16. pii: S0748-7983(17)30038.
    PubMed     Text format     Abstract available


    Int J Cancer

  93. ROSNER B, Eliassen AH, Toriola AT, Chen WY, et al
    Weight and weight changes in early adulthood and later breast cancer risk.
    Int J Cancer. 2017 Jan 30. doi: 10.1002/ijc.30627.
    PubMed     Text format     Abstract available


    Int J Oncol

  94. TRIANTAFILLU UL, Park S, Klaassen NL, Raddatz AD, et al
    Fluid shear stress induces cancer stem cell-like phenotype in MCF7 breast cancer cell line without inducing epithelial to mesenchymal transition.
    Int J Oncol. 2017 Jan 30. doi: 10.3892/ijo.2017.3865.
    PubMed     Text format     Abstract available

  95. JIANG W, Li X, Li T, Wang H, et al
    Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer.
    Int J Oncol. 2017 Jan 24. doi: 10.3892/ijo.2017.3860.
    PubMed     Text format     Abstract available


    J Biol Chem

  96. NAKANO M, Fukami T, Gotoh S, Nakajima M, et al
    A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
    J Biol Chem. 2017 Feb 10. pii: jbc.M117.775684. doi: 10.1074/jbc.M117.775684.
    PubMed     Text format     Abstract available


    J Clin Oncol

  97. ZARDAVAS D, Suter TM, Van Veldhuisen DJ, Steinseifer J, et al
    Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stud
    J Clin Oncol. 2016 Oct 23:JCO2015657916. doi: 10.1200/JCO.2015.65.7916.
    PubMed     Text format     Abstract available

  98. SYMMANS WF, Wei C, Gould R, Yu X, et al
    Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    J Clin Oncol. 2017 Jan 30:JCO2015631010. doi: 10.1200/JCO.2015.63.1010.
    PubMed     Text format     Abstract available

  99. LOIBL S, Denkert C
    How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
    J Clin Oncol. 2017 Jan 30:JCO2016713503. doi: 10.1200/JCO.2016.71.3503.
    PubMed     Text format    


    J Natl Cancer Inst

  100. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109:2-3.
    PubMed     Text format    

  101. HAAS JS
    The Complexity of Achieving the Promise of Precision Breast Cancer Screening.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    

  102. SHIEH Y, Eklund M, Madlensky L, Sawyer SD, et al
    Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    J Pathol

  103. BELLANGER A, Donini CF, Vendrell JA, Lavaud J, et al
    The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.
    J Pathol. 2017 Feb 16. doi: 10.1002/path.4882.
    PubMed     Text format     Abstract available


    J Surg Oncol

  104. VERDIAL FC, Etzioni R, Duggan C, Anderson BO, et al
    Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening.
    J Surg Oncol. 2017 Feb 14. doi: 10.1002/jso.24579.
    PubMed     Text format     Abstract available

  105. FREITAS-JUNIOR R, Gagliato DM, Moura Filho JW, Gouveia PA, et al
    Trends in breast cancer surgery at Brazil's public health system.
    J Surg Oncol. 2017 Feb 6. doi: 10.1002/jso.24572.
    PubMed     Text format     Abstract available

  106. ALCANTARA VS, Lim GH, Lim SH, Sultana R, et al
    Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia.
    J Surg Oncol. 2017 Feb 7. doi: 10.1002/jso.24559.
    PubMed     Text format     Abstract available

  107. DOSSETT LA, Abbott AM, Sun W, Loftus L, et al
    Factors predictive of failure to complete planned intraoperative breast radiation using the intrabeam(R) system.
    J Surg Oncol. 2016;114:930-932.
    PubMed     Text format     Abstract available


    JAMA

  108. NANGIA J, Wang T, Osborne C, Niravath P, et al
    Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
    JAMA. 2017;317:596-605.
    PubMed     Text format     Abstract available

  109. HIMELSTEIN AL, Foster JC, Khatcheressian JL, Roberts JD, et al
    Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    JAMA. 2017;317:48-58.
    PubMed     Text format     Abstract available

  110. BRAGG F, Holmes MV, Iona A, Guo Y, et al
    Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
    JAMA. 2017;317:280-289.
    PubMed     Text format     Abstract available

  111. KURIAN AW, Griffith KA, Hamilton AS, Ward KC, et al
    Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
    JAMA. 2017;317:531-534.
    PubMed     Text format    

  112. RUGO HS, Klein P, Melin SA, Hurvitz SA, et al
    Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
    JAMA. 2017;317:606-614.
    PubMed     Text format     Abstract available


    Lancet

  113. THE LANCET
    Trastuzumab emtansine and cost-based decision making.
    Lancet. 2017;389:2.
    PubMed     Text format    


    Lancet Oncol

  114. BROWER V
    Letrozole not superior to anastrozole for early breast cancer.
    Lancet Oncol. 2017 Feb 2. pii: S1470-2045(17)30081.
    PubMed     Text format    


    NPJ Breast Cancer

  115. CLARE SE, Shaw PL
    "Big Data" for Breast Cancer: Where to look and what you will find.
    NPJ Breast Cancer. 2016;2.
    PubMed     Text format     Abstract available


    Oncogene

  116. JHAN JR, Andrechek ER
    Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
    Oncogene. 2017 Jan 30. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available

  117. HE Y, Northey JJ, Pelletier A, Kos Z, et al
    The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.
    Oncogene. 2017 Jan 30. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available

  118. LIN C, Liao W, Jian Y, Peng Y, et al
    CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    Oncol Rep

  119. XU H, Qian M, Zhao B, Wu C, et al
    Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells.
    Oncol Rep. 2017;37:1619-1626.
    PubMed     Text format     Abstract available

  120. ZHONG ZF, Tan W, Tian K, Yu H, et al
    Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro.
    Oncol Rep. 2017 Feb 10. doi: 10.3892/or.2017.5435.
    PubMed     Text format     Abstract available

  121. MEYNARD G, Mansi L, Lebahar P, Villanueva C, et al
    First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
    Oncol Rep. 2017;37:1573-1578.
    PubMed     Text format     Abstract available


    Oncology

  122. KIM HY, Jung YJ, Lee SH, Jung HJ, et al
    Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis.
    Oncology. 2017 Jan 28. doi: 10.1159/000455143.
    PubMed     Text format     Abstract available

  123. DOHOU J, Mouret-Reynier MA, Kwiatkowski F, Arbre M, et al
    A Retrospective Study on the Onset of Menopause after Chemotherapy: Analysis of Data Extracted from the Jean Perrin Comprehensive Cancer Center Database Concerning 345 Young Breast Cancer Patients Diagnosed between 1994 and 2012.
    Oncology. 2017 Feb 8. doi: 10.1159/000455049.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  124. KELLY JR, Evans S
    Accelerated Partial Breast Irradiation for Breast Cancer: Not Ready for Routine Use.
    Oncology (Williston Park). 2017;31.
    PubMed     Text format    

  125. KUSKE RR
    Accelerated Partial Breast Irradiation for Breast Cancer: An Innovative Option for Selected Early-Stage Cancers.
    Oncology (Williston Park). 2017;31.
    PubMed     Text format    

  126. SZEKELY B, Silber AL, Pusztai L
    New Therapeutic Strategies for Triple-Negative Breast Cancer.
    Oncology (Williston Park). 2017;31.
    PubMed     Text format     Abstract available


    PLoS One

  127. SIEUWERTS AM, Schrijver WA, Dalm SU, de Weerd V, et al
    Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
    PLoS One. 2017;12:e0171343.
    PubMed     Text format     Abstract available

  128. TAKEDA T, Yamamoto H, Kanzaki H, Suzawa K, et al
    Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    PLoS One. 2017;12:e0171356.
    PubMed     Text format     Abstract available

  129. FAN M, Li H, Wang S, Zheng B, et al
    Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.
    PLoS One. 2017;12:e0171683.
    PubMed     Text format     Abstract available

  130. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    PLoS One. 2017;12:e0170634.
    PubMed     Text format     Abstract available

  131. CONTE F, Fiscon G, Chiara M, Colombo T, et al
    Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer.
    PLoS One. 2017;12:e0171661.
    PubMed     Text format     Abstract available

  132. JANG MH, Kim HJ, Chung YR, Lee Y, et al
    A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
    PLoS One. 2017;12:e0172031.
    PubMed     Text format     Abstract available

  133. TERRENATO I, D'Alicandro V, Casini B, Perracchio L, et al
    A cut-off of 2150 cytokeratin 19 mRNA copy number in sentinel lymph node may be a powerful predictor of non-sentinel lymph node status in breast cancer patients.
    PLoS One. 2017;12:e0171517.
    PubMed     Text format     Abstract available

  134. AKUOKO CP, Armah E, Sarpong T, Quansah DY, et al
    Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa.
    PLoS One. 2017;12:e0171024.
    PubMed     Text format     Abstract available

  135. HUANG NS, Quan CL, Mo M, Chen JJ, et al
    A prospective study of breast anthropomorphic measurements, volume and ptosis in 605 Asian patients with breast cancer or benign breast disease.
    PLoS One. 2017;12:e0172122.
    PubMed     Text format     Abstract available

  136. AUGUSTE A, Cortet M, Dabakuyo-Yonli TS, Launay L, et al
    Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.
    PLoS One. 2017;12:e0170069.
    PubMed     Text format     Abstract available

  137. GOMES-ROCHETTE NF, Souza LS, Tommasi BO, Pedrosa DF, et al
    Association of PvuII and XbaI polymorphisms on estrogen receptor alpha (ESR1) gene to changes into serum lipid profile of post-menopausal women: Effects of aging, body mass index and breast cancer incidence.
    PLoS One. 2017;12:e0169266.
    PubMed     Text format     Abstract available

  138. AZIZ S, Wik E, Knutsvik G, Klingen TA, et al
    Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.
    PLoS One. 2017;12:e0171853.
    PubMed     Text format     Abstract available

  139. QIAN XL, Zhang J, Li PZ, Lang RG, et al
    Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
    PLoS One. 2017;12:e0171169.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: